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Loss of RNA expression and allele-speciﬁc
expression associated with congenital heart
disease
David M. McKean1,2, Jason Homsy1,2,3, Hiroko Wakimoto1, Neil Patel4, Joshua Gorham1, Steven R. DePalma1,5,
James S. Ware1,6,7, Samir Zaidi8, Wenji Ma9, Nihir Patel4, Richard P. Lifton8,10, Wendy K. Chung11, Richard Kim12,
Yufeng Shen9,13, Martina Brueckner8, Elizabeth Goldmuntz14, Andrew J. Sharp4,15, Christine E. Seidman1,2,5,*,
Bruce D. Gelb4,15,16,* & J.G. Seidman1
Congenital heart disease (CHD), a prevalent birth defect occurring in 1% of newborns, likely
results from aberrant expression of cardiac developmental genes. Mutations in a variety of
cardiac transcription factors, developmental signalling molecules and molecules that modify
chromatin cause at least 20% of disease, but most CHD remains unexplained. We employ
RNAseq analyses to assess allele-speciﬁc expression (ASE) and biallelic loss-of-expression
(LOE) in 172 tissue samples from 144 surgically repaired CHD subjects. Here we show that
only 5% of known imprinted genes with paternal allele silencing are monoallelic versus 56%
with paternal allele expression—this cardiac-speciﬁc phenomenon seems unrelated to CHD.
Further, compared with control subjects, CHD subjects have a signiﬁcant burden of both LOE
genes and ASE events associated with altered gene expression. These studies identify
FGFBP2, LBH, RBFOX2, SGSM1 and ZBTB16 as candidate CHD genes because of signiﬁcantly
altered transcriptional expression.
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C
ongenital heart disease (CHD)-causing mutations have
been identiﬁed in 450 genes including transcription
factors, signalling molecules1–3 and chromatin modiﬁers4–8,
which direct the temporal and spatial expression of genes during
cardiac development. Recent studies have estimated that there are
B400 genes that can harbour loss or gain-of-function mutations
that cause CHD (denoted CHD genes)4,8. We hypothesized that
other CHD genes could be identiﬁed by altered expression of one
(allele-speciﬁc expression (ASE)) or both alleles (loss-of-expression
(LOE); Fig. 1).
ASE occurs when transcription from one allele is selectively
silenced or enhanced, or when transcripts undergo selective post-
transcriptional degradation (for example, nonsense-mediated
decay; NMD). ASE occurs physiologically to control dosage
effects of chromosome X-encoded genes in females9 and to
silence the maternal or paternal allele of imprinted genes10.
Transcription of one allele can be suppressed by allele-speciﬁc
chromatin marks11, long noncoding RNAs12 or gene regulatory
element mutations13. Other ASE studies include all genes where
one allele is expressed at a statistically higher level than the other
allele, an approach that estimates hundreds of ASE events per
tissue and thousands of ASE events per cell; however, this strategy
likely results in signiﬁcant overestimates of ASE-event rates14–16.
We studied ASE in discarded tissues from CHD patients,
hypothesizing that ASE events likely to cause CHD should result
in substantial allele bias in the expressed transcripts. Hence, we
focused on genes that are expressed in fetal heart that (1) are
normally biallelically expressed and (2) exhibit extreme ASE
(that is, 486% expression of one allele relative to the other).
Moreover, we suggest that ASE per se would not be enough to
cause a disease phenotype, particularly if dosage compensation
resulted in overall normal gene expression. Thus, we focused on
extreme ASE events, either with signiﬁcantly altered gene
expression or in which a deleterious mutation was detected in
the expressed allele (Fig. 1) as candidate CHD genes.
Biallelic LOE (caused by inadequate trans-acting factors,
or combinations of gene regulatory mutations and/or NMD)
can cause CHD by either dominant or recessive mechanisms.
To identify LOE genes potentially responsible for CHD, we
focused on genes (1) that are highly expressed (upper quartile
of expressed genes), (2) with tightly regulated cardiovascular
expression and (3) with signiﬁcantly downregulated (410-fold)
expression.
We demonstrate that 24% of extreme ASE events in CHD
subjects are associated with signiﬁcantly altered levels of gene
expression (compared with 0% of extreme ASE events in control
subjects). We identify nine genes in CHD subjects that are
functionally null—three due to ASE with a damaging mutation in
the expressed allele and six due to biallelic LOE. We propose
FGFBP2, LBH, RBFOX2, SGSM1 and ZBTB16 as especially strong
candidate CHD genes.
Results
RNAseq expression analyses of CHD subjects and controls.
To identify cardiac gene expression, we studied 144 probands
(average age, 2.9 years; range, fetal to 21 years) enrolled in the
Pediatric Cardiac Genomics Consortium17 and performed RNA
sequencing (RNAseq) on 172 surgically discarded cardiovascular
tissues (Supplementary Data 1 and 2). We also studied gene
expression data from ‘normal’ adult (average age, 49.3 years;
range, 20–70 years) cardiac tissues (n¼ 87, left ventricle; n¼ 26,
right atria) from the Genotype-Tissue Expression Consortium18
(GTEx, n¼ 95 subjects; Supplementary Data 3 and 4) and fetal
cardiac tissues without CHD (n¼ 5, gestational age 15–16 weeks).
RNA expression was measured using standard RNAseq
procedures (see Methods). The 172 CHD samples were obtained
from eight different cardiovascular tissues (aorta, atrial septum,
ductus arteriosus, interventricular septum, left ventricle, pulmon-
ary artery, right atrium and right ventricle; Supplementary Data 2
and Supplementary Table 1) with at least six samples per tissue.
Approximately 15,300 expressed genes were expressed in each
sample (two or more aligned reads per million (r.p.m.); Fig. 2a
(grey bars) and Supplementary Table 1), and the average
number of genes expressed per subject per tissue ranged from
14,938 (interventricular septum) to 15,883 (pulmonary artery).
Expression analyses were performed by comparing single samples
to the mean of all other samples of the same tissue type
(for example, right atrial CHD sample versus all other right atrial
CHD samples).
Identiﬁcation of extreme ASE events. To detect extreme ASE
events in genes that are normally biallelically expressed, single-
nucleotide polymorphisms (SNPs) were identiﬁed from whole
exome4,8 (WES, n¼ 130) or genome (WGS, n¼ 14) sequencing
of CHD probands and available unaffected parents. SNPs were
identiﬁed in GTEx donors from Illumina Exome and 5M SNP
arrays. At each genomic heterozygous SNP (see Methods), an
allele ratio (reference RNAseq reads/alternate RNAseq reads) was
computed (Supplementary Fig. 1). To focus on ASE events in
genes with normal biallelic expression, SNPs with typical biased
expression were excluded (see Methods, Supplementary Fig. 1
and Supplementary Table 2). SNPs were then phased using
parental genotypes or by assuming that the most highly expressed
base at each SNP is encoded by the same allele. Compound
allele ratios were then calculated for each gene as the ratio
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Figure 1 | Identiﬁcation of extreme ASE genes in subjects with CHD.
Shown are both alleles of a gene that differ by the SNP haploblocks ‘CC’
(blue) and ‘GT’ (red), as identiﬁed by WES, WGS or SNP-array genotyping.
RNAseq analysis (read counts at heterozygous positions) reveals the
expression of both alleles (biallelic RNA expression) or the disproportionate
expression of one allele over another (ASE). RNAseq expression analyses
(comparing each sample to the average of all other samples within a tissue
group) identify relative loss and gain of expression. Variant analysis, in
conjunction with RNAseq analysis, can further identify LOF mutations in the
expressed allele (*).
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of the summed reads corresponding to each allele (Methods).
This phasing methodology was 98% accurate in F1 mouse tissues
(M. musculus  M. castaneus; Supplementary Table 3) and 100%
accurate in three human WGS trios (affected proband and
unaffected parents), when we applied a compound allele ratio
threshold Z7 (Supplementary Fig. 2c). Transcripts with a
compound allele ratio Z7.2 and a binomial P valueo0.01
(Bonferroni-corrected for the number of expressed genes with
heterozygous SNPs (Supplementary Data 2 and 4)) were
designated as having extreme ASE. Finally, both over-
represented ASE genes (that is, 45% of subjects including at
least one control subject have ASE events in the same gene;
Supplementary Table 4) and ASE events in genes with low fetal
heart expression (Supplementary Table 5) were removed.
DNA-sequencing methodology strongly inﬂuenced extreme
ASE detection (Fig. 2b). WGS and WES data yielded 5.1 and 1.4
extreme ASE events per CHD subject, respectively; SNP arrays
yielded 3.3 extreme ASE events per GTEx donor. In total,
we detected 607 extreme ASE events; 491 events in 17 known
imprinted genes19 (Supplementary Data 5 and www.geneimprint.
com) and 116 events (CHD, 56; GTEx, 60; Supplementary
Tables 6 and 7) in genes normally biallelically expressed. Dideoxy
sequencing of cDNAs from CHD tissues conﬁrmed 17/17
ASE events in imprinted genes (100% validation rate), and
45/56 ASE events in non-imprinted genes (80% validation rate;
Supplementary Figs 3 and 4 and Supplementary Data 6).
Imprinting in cardiovascular tissues. Because parental gene
imprinting is a major cause of ASE in mammalian tissues, we
assessed imprinting in cardiovascular tissues. The set of genes
imprinted in fetal and/or neonatal cardiovascular tissues has not
been described. Forty-eight genes previously identiﬁed as being
imprinted in non-cardiac tissues were expressed in fetal heart and
also contained heterozygous SNPs. These were evaluated for ASE
in cardiovascular tissues. Seventeen genes had ASE in at least 50%
of CHD and GTEx subjects (Table 1), whereas 31 were
predominantly biallelically expressed (Supplementary Table 8).
Gene imprinting in mouse cardiovascular tissues was the same as
in human cardiovascular tissues except for three genes: CDKN1C,
IGF2R and SGCE. These three genes are biallelically expressed
in human hearts, but have ASE in mouse hearts. Biallelic
expression of these same genes in other human tissues has been
described20–22. After excluding differences that were attributable
to genotyping methods, ASE of imprinted genes was
indistinguishable in CHD proband tissues and GTEx tissues.
ASE events in known imprinted genes were excluded from
further analyses.
Extreme ASE is attributable to NMD in a minority of cases.
We identiﬁed 78 rare, nonsense mutations in genes that were
expressed at sufﬁcient levels to evaluate ASE in CHD probands
(Supplementary Table 9). Only 14/78 (18%) genes exhibited
NMD and had signiﬁcantly reduced expression of the allele
harbouring the LOF mutation, even after employing a less
stringent deﬁnition of ASE (allele bias 44). This low percentage
of NMD is consistent with previous reports23. Unfortunately,
this analysis could not be performed on GTEx samples because
complete coding sequence data were unavailable for these
subjects.
Of the 45 extreme ASE events observed in CHD probands
(Supplementary Table 6), seven ASE events (Table 2) resulted
from nonsense (ASPN, CTSA, PGM1 and RBFOX2), splice site
(AARSD1) or frameshift (C7 and RETSAT) variants that caused
NMD. In sum, 38/45 (85%) extreme ASE events in CHD
probands remain unexplained and could potentially reﬂect
mutations in gene regulatory elements.
Extreme ASE genes have signiﬁcant expression changes.
We hypothesized that genes whose expression levels differ
between subjects with extreme ASE versus subjects with biallelic
expression are candidate CHD genes. After excluding eight CHD
and three GTEx tissues that failed quality controls (Methods), we
compared gene expression in 37 extreme ASE genes in CHD
subjects and 57 extreme ASE genes in GTEx subjects to the mean
expression of biallelically expressed samples of the same tissue
type (for example, right atrial ASE expression compared with
right atrial biallelic expression). In CHD subjects, upregulated
ASE genes (fold 45, Po0.05, P calculated from z-score))
included MYOZ1 and FGFBP2 (observed in two subjects) and
downregulated ASE genes (fold o0.65, Po0.05, P calculated
from z-score) included SGSM1, AARSD1, C5orf46, SDHB, CBR1
and RBFOX2 (Table 3). By contrast, no extreme ASE gene had
signiﬁcantly different expression in GTEx subjects.
Identiﬁcation of functionally null genes. We identiﬁed CHD
gene candidates who had extreme ASE and harboured a dele-
terious mutation in the expressed allele, and so are unlikely to
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Figure 2 | Extreme ASE genes preferentially identiﬁed in WGS subjects. Shown in a are the number of genes with a minimum expression of 2 r.p.m.
(grey bars), and the number of expressed genes that contain heterozygous SNPs (black bars) for CHD WGS (n¼ 30 tissues) and CHD WES probands
(n¼ 142 tissues), GTEx donors (n¼ 113 tissues) and mouse C57Bl6/Castaneus F1 hybrids (n¼ 7 tissues). s.d. is indicated. b The distribution of extreme
ASE events per subject by genotyping platform. Extreme ASE events were identiﬁed in 470% of WGS subjects (n¼ 14). However, extreme ASE events
were identiﬁed in only B20% of WES subjects (n¼ 130) and B45% of GTEx donors (n¼ 95).
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make functional protein. Three extreme ASE genes, C17orf97,
CRACR2B and FGFBP2, encoded rare, putatively deleterious
variants in the expressed allele (Table 2). Although FGFBP2 has
relatively common ASE (45% of subjects (Supplementary
Table 6)), its functional null status makes it a candidate-
recessive CHD gene. These analyses could not be performed in
GTEx samples.
Biallelic LOE of genes that are typically both highly expressed
and tightly regulated are another class of functionally null genes
that may cause CHD. We identiﬁed genes with biallelic LOE (fold
o0.1, Po2.7 10 3 (z-scoreo 3), P calculated from z-score)
in six CHD probands (Table 3) but none in GTEx donors
(P¼ 7.8 10 3, Fisher Exact test). Five LOE genes, LBH, FRG1B,
PHKG1, IRX5 and ZBTB16, have no homozygous LOF variants
in the Exome Aggregation Consortium (ExAC) database
(exac.broadinstitute.org), while TRMT2B, an X-linked gene, is
hemizygous in a signiﬁcant number of subjects. Signiﬁcant
downregulation of all biallelic LOE genes was conﬁrmed using
quantitative PCR (qPCR; Supplementary Table 10), although this
analysis identiﬁed only an approximately threefold reduction in
FRG1B and IRX5. Biallelic LOE of PHKG1 and IRX5 occurred in
two subjects both with Kabuki syndrome (MIM147920 (ref. 7)),
caused by damaging de novo KMT2D mutations4.
Discussion
Our transcriptome analyses of tissues from CHD patients
identiﬁed several CHD gene candidates, including RBFOX2,
Table 1 | ASE of imprinted genes in cardiovascular tissues.
Gene Chr:Pos (hg19) CHD ASE* GTEx ASE* % ASE Coding/noncoding Expressed allele FHE Mouse
ZDBF2 chr2:207139522-207179148 4/7 15/15 86 C P 8.2 ASEw
NAP1L5 chr4:89617065-89619023 9/10 14/14 96 C P 18.3 NE
FAM50B chr6:3849631-3851551 4/5 22/23 93 C P 37.9 NE
PLAGL1 chr6:144261436-144385735 16/16 33/34 98 C P 39.7 ASE
PEG10 chr7:94285636-94299006 1/1z 0/0 100 C P 98.8 ASE
MEST chr7:130126015-130146138 7/8 1/1 89 C P 47.7 ASE
H19
IGF2
chr11:2016405-2170833
chr11:2016405-2170833
12/12
4/4
68/69
1/1
99
100
NC
C
M
P
3287
2677
ASE
ASE
DLK1
MEG3
RTL1
chr14:101193201-101373305
chr14:101193201-101373305
chr14:101193201-101373305
17/17
5/5
1/1z
39/40
2/8
0/0
98
54
100
C
NC
C
P
M
M
76.4
285.3
3.2
ASE
ASE
ASEw
MAGEL2
NDN
SNRPN
SNURF
chr15:23888695-25244225
chr15:23888695-25244225
chr15:23888695-25244225
chr15:23888695-25244225
2/2
55/55
60/60
0/0
0/0
NS
48/48
4/4
100
100
100
100
C
C
C
C
P
P
P
P
3.9
63.8
68.9
99.1
ASEw,y
ASE
ASE
ASE
PEG3 chr19:57321444-57352094 14/15 14/17 88 C P 103.2 ASE
NNAT chr20:36149606-36152090 1/2 0/0 50 C P 21.1 NS
ASE, allele-speciﬁc expression; CHD, congenital heart disease; FHE, fetal heart expression (reads per million aligned reads); GTEx, Genotype-Tissue Expression Consortium; M, maternal; NE, not
expressed; NS, no SNP; P, paternal; SNP, single-nucleotide polymorphism.
*Number subjects with silenced allele/number of informative subjects.
wMouse ASE observed in pulmonary artery.
zPEG10 and RTL1 are not expressed in postnatal cardiac tissues and are silenced in the only fetal subject in the study.
yMouse ASE observed in skeletal muscle.
Table 2 | Extreme ASE genes with LOF variants in silenced allele or damaging variants in expressed allele.
Gene ID Mutation Predicted
effect
CADD
score
ASE
effect
MAF FHE PCGC cases
LOF AF
PCGC controls
LOF AF
ExAC LOF
AF
Rare LOF mutations in silenced allele-likely NMD
AARSD1 1-00384 chr17:41102746C4A Spl Acceptor* 24.2 NMD 4.1 10 5 138 0 0 0
RBFOX2w 1-05368 chr22:36155972G4A Nonsense 26.9 NMD 0 235.0 1.4 10 3 0 1.8 10 5
PGM1 1-01021 chr1:64100580G4T Nonsense 40 NMD 0 124.2 0 0 6.4 10 5
ASPN 1-05398 chr9:95228784G4A Nonsense 36 NMD 4.1 10 5 16.9 0 1.1 10 3 3.5 104
CTSA 1-01620 chr20:44522702C4A Nonsense ND NMD 0 122.3 0 2.7 104 6.9 104
C7 1-00070 chr5:40945362TACG
TCGACAGA4T
Frameshift NA NMD 0 156.7 2.8 10 3 5.6 104 1.4 10 3
RETSAT 1-01024 chr2:85571195TCA4T Frameshift NA NMD 1.2 10 3 15.8 5.6 10 3 5.6 10 3 9.7 10 3
Rare damaging missense mutation in expressed allele-likely LOF
FGFBP2z 1-01984 chr4:15964134A4C p.Trp207Gly 15.41 Null 6.3 104 0y 0|| 0|| 1.6 10 5 ||
C17orf97 1-01485 chr17:260239C4T p.Arg30Trp 17.77 Null 3.5 104 16.8 0|| 0|| 0||
CRACR2B 1-04333 Chr11:829356G4A Spl Acceptorz NA Null 4.4 104 20.9 0|| 0|| 0||
AF, allele frequency; ASE, allele-speciﬁc expression; CADD, combined annotation-dependent depletion; CHD, congenital heart disease; ExAC, Exome Aggregation Consortium; FHE, fetal heart expression
(reads per million aligned reads); LOF, loss-of-function; MAF, minor allele frequency in ExAC; NMD, nonsense-mediated decay; PA, pulmonary artery; PCGC, Pediatric Cardiac Genomics Consortium; PV,
pulmonary valve.
*Consensus splice site mutation (within ﬁrst two bases of intron).
wMutation is de novo.
zStrong candidate CHD gene (identiﬁed in this study).
yFGFBP2 is not expressed in fetal heart, but is expressed in PA and PV.
||Frequency of homozygous (ExAC) or combined homozygous and compound heterozygous (PCGC cases and controls) LOF mutations.
zNonconsensus splice site mutation.
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a recently discovered deﬁnitive CHD gene8. Although two LOE
genes, FRG1B and TRMT2B, have no known role in cardiac
development, the known functions of other candidate genes
increase the likelihood that altered expression could cause CHD.
In addition, we identiﬁed two novel ﬁndings related to
cardiovascular imprinted genes.
There were no signiﬁcant differences in imprinting between
CHD and GTEx subjects, suggesting that imprinting defects are
not a common cause of CHD. However, we note the following
unexpected observations. First, the imprinted gene RTL1 has
maternal ASE in both human and mouse cardiovascular tissues
(Table 1 and Supplementary Table 11) but the opposite (paternal)
allele is expressed in other fetal and placental tissues24,25.
Temporal and spatial-dependent parental allele switching has
been observed in only two other imprinted genes, GRB10 and
IGF2 (refs 26,27). Second, RTL1 is the only protein-coding,
imprinted gene with maternal ASE in cardiovascular tissues.
Imprinted genes in other tissues do not have a signiﬁcant
maternal or paternal bias. In cardiac tissues, imprinted gene
clusters were signiﬁcantly biased (P¼ 0.008, Fisher Exact test) for
paternal ASE (11 ASE; 8 biallelic) versus maternal ASE (1 ASE; 12
biallelic). Only 5% (1/21) of maternally expressed, imprinted
genes had ASE, while 56% of paternally expressed, imprinted
genes (14/25) had ASE (P¼ 3.1 10 4, Fisher Exact test).
Together, these data suggest a cardiac-speciﬁc mechanism that
removes imprinting ‘marks’ that would normally silence maternal
allele expression.
Although extreme ASE events were identiﬁed in both CHD
and GTEx subjects, ASE associated with signiﬁcantly altered gene
expression was observed only in CHD subjects (9/37 CHD
subjects; 0/57 GTEx subjects; P¼ 1.1 10 4, Fisher Exact test).
As genes with extreme ASE and downregulated expression could
phenocopy genes harbouring loss-of-function (LOF) mutations in
one allele (ignoring potential dominant-negative effects), we
compared the LOF allele frequency (AF) between CHD and
control data sets. Five of six ASE genes with reduced expression
are constrained and have a low frequency (o0.001) of LOF
mutations in the ExAC database (Table 3). Three of these,
AARSD1, SDHB and C5orf46, have no known functions in the
heart. The other two genes, RBFOX2 and SGSM1, are strong
candidates for contributing to CHD. Prior WES analyses
identiﬁed de novo RBFOX2 LOF variants in four CHD probands
(including the subject with ASE), and SGSM1 LOF variants in two
CHD probands (one each de novo and inherited), but no RBFOX2
or SGSM1 LOF variant in 1,800 controls3,4,8. The LOF AF
was signiﬁcantly higher in CHD probands for both RBFOX2
(CHD AF¼ 1.4 10 3; ExAC AF¼ 1.8 10 5; odds ratio
(OR)¼ 78; P¼ 6.6 10 5, Fisher Exact test) and SGSM1
(CHD AF¼ 9.4 10 4; ExAC AF¼ 9.1 10 5; OR¼ 10.4;
P¼ 0.02, Fisher Exact test) than observed in B55,000 control
exomes. Moreover, the estimated odds ratio for SGSM1 is
conservative as we excluded both the subjects with ASE and
another CHD subject with markedly reduced biallelic expression
(1-02922: 0.19-fold, P¼ 0.02, P calculated from z-score).
FGFBP2, another strong CHD gene candidate, is predicted to
lack all gene functions in two CHD subjects, through two
different mechanisms. One subject had extreme ASE with a
deleterious mutation in the expressed allele (Table 2), while the
other subject is predicted to have complete loss of FGFBP2 gene
function due to severely reduced biallelic expression (1-02697,
Table 3 | Extreme ASE and biallelic LOE events with signiﬁcantly altered gene expression.
Gene ID Tissue Proband
Expr*
Mean Expr ±s.d.
(n)
Fold P valuew PCGC cases LOF
AF
PCGC controls LOF
AF
ExAC LOF
AF
ASE genes with loss of allele expression
RBFOX2z,y 1-05368 DuctArt 189.1 296±44 (15) 0.64 1.6 10 2 1.4 10 3 0 1.8 10 5
SGSM1z,y 1-01019 RA 60.3 133±51 (18) 0.45 4.7 10 2 9.4 104 0 9.1 10 5
AARSD1 1-00384 IVS 65.9 108±12 (7) 0.61 3.0 104 0 0 0
C5orf46 1-00713 LV 7.7 42±17 (9) 0.18 4.4 10 2 0 0 9.1 10 5
SDHB C417-01
C417-01
IVS
LV
169.6
124.0
302±25 (7)
224±46 (9)
0.56
0.55
o1.0 104
3.0 10 2
0 0 8.2 10 5
CBR1 CHD-1548
CHD-1548
CHD-1548
LA
LV
RA
12.9
15.1
10.6
29±6.0 (10)
25±3.0 (7)
26±3.4 (9)
0.44
0.60
0.41
6.1 10 3
8.0 104
o1.0 104
0 2.8 104 2.6 10 3
ASE genes with gain of allele expression
FGFBP2 1-01024 RA 5.6 1.0±1.7 (15) 5.48 6.7 10 3 9.5 104 5.6 104 4.5 104
FGFBP2 1-01984 LA 9.2 1.4±0.4 (3) 6.86 o1.0 104 9.5 104 5.6 104 4.5 104
MYOZ1 1-02697 RV 26.9 4.2±3.5 (16) 6.45 o1.0 104 0 2.7 104 3.5 104
Genes with loss of expression of both alleles
LBHy 1-03051 AO 5.4 55±15 (6) 0.10 8.0 104 0|| 0|| 0||
ZBTB16y 1-03316 AO 1.2 22±5.8 (6) 0.06 3.0 104 0|| 0|| 0||
IRX5 1-03948z RV 0.6 13±4.1 (20) 0.05 1.9 10 3 0|| 0|| 0||
PHKG1 1-00596z RA 2.6 30±8.7 (47) 0.09 1.5 10 3 0|| 0|| 1.6 10 5||
FRG1B 1-04119 PA 0.3 5.4±1.1 (10) 0.06 o1.0 104 0|| 0|| 0||
TRMT2B 1-02921 RV 0.0 5.5±1.3 (20) 0 o1.0 104 0|| 0|| 2.6 104||
PHKG1# 1-03948z RV 0.6 15±8.1 (20) 0.04 4.0 10 2 0|| 0|| 1.6 10 5||
FGFBP2#,y 1-02697 PV 0.5 14±3.4 (3) 0.04 1.0 104 0|| 0|| 1.6 10 5||
AF, allele frequency; AO, aorta; ASE, allele-speciﬁc expression; CHD, congenital heart disease; DuctArt, ductus arteriosus; ExAC, Exome Aggregation Consortium; IVS, interventricular septum; LA, left
atrium; LOE, loss-of-expression; LOF, loss-of-function; LV, left ventricle; PA, pulmonary artery; PCGC, Pediatric Cardiac Genomics Consortium; PV, pulmonary valve; RA, right atrium; RV, right ventricle.
*Expression in reads per million aligned reads.
wP value calculated from z-score.
zIncludes de novo LOF mutations.
yStrong candidate CHD genes (identiﬁed in this study).
||Frequency of homozygous (ExAC) or combined homozygous and compound heterozygous (PCGC cases and controls) LOF mutations.
zKMT2D de novo mutations identiﬁed in both 1-03948 (LOF) and 1-00596 (damaging-missense).
#LOE genes PHKG1 (1-03948, P42.7 10 3) and FGFBP2 (1-02697, n¼ 3) are not signiﬁcant on their own, but occur in genes signiﬁcant in other subjects.
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Table 3). Notably, FGFBP2 is a component of the FGF signalling
axis that regulates outﬂow tract and valve morphogenesis28, and
both CHD subjects with abrogated FGFBP2 expression have
outﬂow tract defects.
Two probands with abnormal valve development had biallelic
LOE of LBH (limb bud and heart) or ZBTB16. LBH, a cardiac
developmental transcriptional co-activator, mediates neural crest
migration29, which is required for aortic valve formation30.
Overexpression of mouse Lbh produces valvular defects and
decreases Nppa (atrial natriuretic hormone) expression31.
Consistent with this, LOE of LBH in proband 1-03051 was
associated with increased NPPA expression (fold¼ 12.3,
Po0.0001, P calculated from z-score). However, mice lacking
Lbh have no overt cardiovascular defects32. ZBTB16 (also known
as PLZF) is a member of the Krueppel (C2H2-type) zinc-ﬁnger
transcription factor family that regulates expression of GATA4
(ref. 33); GATA transcription factors are important for outﬂow
tract development34. ZBTB16 LOE in proband 1-03316 was
associated with reduced GATA4 expression (0.04-fold, P¼ 0.19,
P calculated from z-score).
Kabuki syndrome is a complex developmental disorder including
CHD caused by mutation in KMT2D, a histone methyltransferase.
Our studies identiﬁed markedly reduced expression of PHKG1 in
two Kabuki syndrome subjects (Table 3) and decreased expression
of IRX5 in one subject. (IRX5 expression is normally low in right
atrial tissues, the only sample available from subject 1-00596.)
Damaging IRX5mutations (MIM611174 (ref. 35)) cause CHD with
conduction abnormalities, marked frontonasal anomalies and
prominent ears, phenotypes that overlap that also occur in
Kabuki syndrome. On the basis of these data, we speculate that
KMT2D regulation of IRX5 and PHKG1 contributes to the
pathogenesis of Kabuki syndrome.
Although we identiﬁed nine ASE events likely related to CHD
in 144 probands, our analyses have several limitations. First, most
of the CHD tissues were acquired after birth, and genes with
aberrant expression that are developmentally downregulated
would escape detection. Second, onlyB25% of cardiac expressed
genes contain heterozygous SNPs per sample, so a large fraction
of ASE genes cannot be detected by our methodology. We also
detected 3.6-fold more ASE genes in subjects genotyped with
WGS than subjects genotyped with WES. WES genotyping does
not evaluate untranslated region (UTR) sequences and, hence,
does not discover SNPs in these regions, resulting in low
efﬁciency of ASE detection in exome-genotyped samples. Finally,
to limit false-positives, we employed stringent deﬁnitions of ASE
(Z7.2 allele ratio; Pr0.01, Bonferroni-corrected binomial
distribution) and LOE (foldo0.1, Po2.7 10 3, P calculated
from z-score) genes, at the expense of under-calling expression
differences. We expect that cardiac RNA expression from more
CHD tissues will explain a larger proportion of disease.
We found that only a small subset of extreme ASE events was
attributable to NMD. Hence, unknown mechanisms accounted
for allele gain/loss of gene expression in the majority (85%) of
extreme ASE events identiﬁed in CHD subjects. While we
speculate that mutations in regulatory sequences may lead to
altered allele-speciﬁc transcription, another contributing factor
could be somatic mutations expressed in cardiovascular tissues,
but not blood (the DNA source for genomic sequencing), that
cause NMD.
In summary, integrated analyses of genomic DNA and RNAseq
in CHD cardiac tissues identiﬁed preferential silencing of
paternally expressed imprinted genes, several extreme ASE and
LOE genes relevant to cardiogenesis and potential downstream
targets of KMT2D. DNA sequence analyses of 81 trios identiﬁed
nine de novo mutations likely responsible for disease4,8.
Assessment of RNAseq data from these and 63 singletons
identiﬁed seven instances (RBFOX2, SGSM1 (n¼ 2), FGFBP2
(n¼ 2), LBH and ZBTB16) with signiﬁcantly reduced gene
expression likely contributing to CHD. These data support the
use of RNAseq analyses in identifying disease genes. We expect
that further study of WGS will identify damaging mutations in
regulatory elements that alter transcription of these CHD genes.
Methods
Patient and control cohorts. CHD probands were recruited from nine centres in
the United States and the United Kingdom into the Congenital Heart Disease
Genetic Network Study of the Pediatric Cardiac Genomics Consortium (CHD
Genes: NCT01196182). The protocol was approved by the Institutional Review
Boards of Boston Children’s Hospital, Brigham and Women’s Hospital, Great
Ormond St Hospital, Children’s Hospital of Los Angeles, Children’s Hospital of
Philadelphia, Columbia University Medical Center, Icahn School of Medicine at
Mount Sinai, University of Rochester School of Medicine and Dentistry, Steven and
Alexandra Cohen Children’s Medical Center of New York and Yale School of
Medicine. Written informed consent was obtained from each participating subject
or parent/guardian. Probands with CHD were selected based on availability of
cardiovascular tissue and RNA quality (RNA integrity number, RIN). Cardiac
diagnoses were obtained from review of echocardiogram, catheterization and
operative reports; extracardiac ﬁndings were extracted from medical records.
The control cohort consisted of RNAseq data from 113 heart tissues (left
ventricle and/or right atrium) from 95 deceased subjects who were enroled in the
GTEx programme. The GTEx data sets used for the analyses described in this
manuscript were obtained from: dbGaP through dbGaP accession number
phs000424.vN.pN on 02 August 2014.
WES and WGS. Exomes of CHD probands were captured and sequenced at the
Yale Center for Genome Analysis, as described4. In brief, gDNA isolated from
venous blood was captured with the NimbleGen v2.0 exome capture reagent
(Roche) and sequenced (Illumina HiSeq 2000, 75 base paired-end reads) to a
mean read depth of 107. Reads were aligned to the hg19 reference genome using
Novoalign (Novocraft), and variants called using HaplotypeCaller (Genotype
Analysis Toolkit, GATK)36. Variants were ﬁltered using the hard ﬁlters
(FisherStrand (FS)o25, quality by depth (QD)o4) for passing variants. Identiﬁed
heterozygous SNPs had a minimum genotype quality score of 50 and an allele
balance (AB, number ALT reads/(number REF readsþ number ALT reads), where
‘ALT’ and ‘REF’ reads refers to reads containing the alternate or reference base in a
heterozygous SNP) between 0.2 and 0.8.
Whole genomes of 11 probands and three trios were sequenced to an average
read depth of 35.2. gDNA libraries were made from 5 mg of puriﬁed DNA and
sequenced on an Illumina HiSeq 2000 (101 base paired-end reads). Reads were
aligned to reference genome hg19 using Novoalign (Novocraft) and variants were
called using UniﬁedGenotyper and ﬁltered by VQSR (GATK36). Heterozygous
SNPs were identiﬁed using the same criteria as for WES.
SNP array genotyping. GTEx subjects were genotyped on both Illumina Exome
and Illumina 5M arrays.
Variant annotation and minor allele frequency. Variants were annotated using
SNPEff 37. Damaging missense variants were predicted using both Polyphen2
(ref. 5) and CADD38. Minor AF (MAF) information for each SNP was extracted
from the ExAC database, containing 455,000 individuals. If AF data were
unavailable from ExAC, the maximum MAF reported in dbSNP, Exome Variant
Server, HapMap or 1000 Genomes was chosen for subsequent calculations.
RNAseq and analyses. RNA was puriﬁed from RNAlater-treated frozen tissue,
using Trizol (Life Technologies). RNA (RIN45) was converted into cDNA and
into RNAseq libraries as described39. In brief, puriﬁed poly-A RNA that had gone
through two rounds of oligo-dT selection was converted into cDNA and then made
into RNAseq libraries. Libraries were sequenced (Illumina HiSeq 2000 or Illumina
HiSeq 2500, 50-base paired-end reads) to a target depth of 420 million reads
(median, 57 million reads; range, 20–530 million reads). Reads were aligned to the
hg19 reference genome using TopHat 1.4 (using the following parameters: ‘-m 1 -a
5 --segment-mismatches 3 --segment-length 25 -g 0 --no-novel-juncs’, with splice
junctions being deﬁned by genes.gtf (Illumina iGenome download)). Mitochondrial
and duplicate reads were discarded using Samtools and Picard’s MarkDuplicates,
respectively. A median of 60% of reads was aligned to the reference genome, hg19,
and 36% of reads uniquely aligned to the nuclear genome. Allele-speciﬁc reads were
tallied using GATK UniﬁedGenotyper at each heterozygous position identiﬁed
by gDNA sequencing (using the following parameters: ‘--genotyping_mode
GENOTYPE_GIVEN_ALLELES --alleles het_snps_only.vcf --output_mode
EMIT_ALL_SITES’ where a personalized vcf ﬁle containing only heterozygous SNP
was used as ‘het_snps_only.vcf’). Gene expression was determined by calculating
reads per gene per million aligned reads (r.p.m.).
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Quality-control metrics for subjects. Some subjects were excluded from our
study. Ignoring SNPs with expected ASE (chromosome X genes, previously
reported imprinted genes, and SNPs within alternatively spliced exons), we
observed that most heterozygous SNPs (with a minimum of 10 reads) were
expressed biallelically (CHD exome (95.7±1.0%), CHD WGS (96.8±0.5%) and
GTEx (97.6±0.6%; Supplementary Fig. 2a). Eight CHD and three GTEx subjects
with substantially lower biallelic SNP expression (o75%; data not shown) were
removed from this study.
Quality-control metrics for SNPs. To ensure accurate ASE identiﬁcation, all
genotyped SNPs observed in RNAseq data were subjected to quality control.
Only SNPs with at least ﬁve reads in RNAseq data or both alleles expressed were
analysed for ASE.
Low-quality genotype called SNPs. Low-quality SNPs observed in either WES or
WGS generally reﬂected either misaligned DNA sequence reads because of gene
orthologues, pseudogenes or other highly similar sequences. As previously
described, low-quality SNPs either failed GATK variant ﬁltration or had
signiﬁcantly biased AB. In addition, genes with a single heterozygous SNP,
expressed at a high level (420 reads), with 100% monoallelic expression were
excluded; the reference base of these SNPs was expressed in 480% of cases
(Supplementary Fig. 2b), indicating a suspicious genotype.
SNPs in alternatively spliced exons. Biased expression of SNPs in alternate exons
could not be evaluated for ASE because we could not differentiate allele-speciﬁc
expression versus allele-speciﬁc splicing. That is, SNPs (Supplementary Data 7,
annotated ‘Filter_SNP_alt_splicing’) in exons that were only found in a subset of
gene isoforms, as represented in three databases (RefGENE.txt (Illumina), UCSC
Genes and Basic Gene Annotations Set (ENCODE/GENCODE)), were excluded.
SNPs with suspected alignment biases. Sequencing reads containing clustered
SNPs (that is, those within 30 bp of two other SNPs) or SNPs in close proximity to
an indel (within 30 bp of an indel) were often not aligned by TopHat/Bowtie
introducing artefacts that appear as allele biases; these SNPs were excluded. In
addition, SNPs in repeat regions (Supplementary Data 7, annotated
‘Filter_SNP_duplicate_sequence’) were excluded if SNP and ﬂanking sequences
(50nt up- and downstream) aligned to multiple genomic locations (identiﬁed with
BLAT (UCSC Genome Browser)) and if the ALT base was the REF base at one of
those multiple locations.
SNPs biased in multiple subjects. Some ‘common’ biased SNPs (biased in440%
of CHD probands or GTEx subjects, with a minimum of three biased subjects)
were present in genes with biallelically expressed SNPs. These common biased
SNPs (except those likely to contribute to NMD) were ﬁltered out as either not
likely to impair cardiac development or as technical artifacts.
Quality-control metrics for genes. Genes expressed in an allele-speciﬁc manner
in many subjects. Excluded genes included all chromosomes X and Y genes,
HLA- genes (that is, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB,
HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2,
HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-E, HLA-F,
HLA-G, HLA-J, HLA-P and HLA-T) and noncoding genes. Coding genes were
identiﬁed by SNPEFF_EFFECT designations: CODON_CHANGE_PLUS_
CODON_DELETION, CODON_CHANGE_PLUS_CODON_INSERTION,
CODON_DELETION, CODON_INSERTION, FRAME_SHIFT, NON_
SYNONYMOUS_CODING, START_GAINED, STOP_GAINED,
SYNONYMOUS_CODING, UTR_3_PRIME, UTR_5_PRIME. In addition, genes
with ASE in45% of subjects, including at least one GTEx subject, are unlikely to
impair cardiac development; these ‘common’ ASE genes are reported in
Supplementary Table 4.
RNAs with misaligned reads. Heterozygous SNPs were excluded if420% of any
other heterozygous SNPs in the same transcript were not expressed, or if a
heterozygous coding SNP was not expressed. This pattern reﬂected misaligned reads.
Genes with low fetal heart expression. RNAs that are unlikely to be involved in
cardiac development (normalized fetal heart expression o2 r.p.m.) were ﬁltered
out (Supplementary Table 5). This ﬁlter removed ﬁve and 24 ASE events from
CHD probands and GTEx donors, respectively.
Quality-control conﬁrmation of extreme ASE. Allele bias observed in both
aligned and unaligned reads (that is fastq ﬁles). As noted above, TopHat/Bowtie
alignment can introduce apparent allele bias into aligned RNAseq data. To conﬁrm
allele bias was not introduced by TopHat/Bowtie alignment, raw, unaligned
sequencing reads containing: 10nt ﬂanking the ALT/REF base, or 20nt either
upstream or downstream of the ALT/REF base, or their reverse complements, were
counted. The numbers of raw sequencing reads containing ALT and REF
sequences were required to be similar to the numbers of ALT and REF aligned
reads. Further, allele balances were required to be similar in both unaligned and
aligned read counts.
Visual inspection of RNAseq data in Integrative Genomics Viewer (Broad
Institute). Biased SNPs (Supplementary Data 7) were ﬁltered out if other SNPs
with biallelic expression were observed in the same gene—this was particularly
important for CHD exome samples, which are not well genotyped in the 30 UTR
and for GTEx samples (in which genotyping was restricted to common SNPs). In
addition, biased SNPs were excluded if visual inspection identiﬁed more than two
alleles. Thirty-nine SNPs (Supplementary Data 7: ‘Filter_SNP_complex_allele_
structure’) had multiple alleles likely due to misalignment of reads from
pseudogenes and/or gene families.
Conﬁrmation of ASE events by Sanger sequencing. At least one biased SNP per
extreme ASE event was analysed using Sanger sequencing. PCR products derived
from RNA were prepared from 200 ng total RNA by incubation with Superscript
III Reverse Transcriptase (Thermo Fisher) and then cDNA was PCR-ampliﬁed
with Phusion polymerase (New England Biolabs) using gene-speciﬁc primers
(Supplementary Data 6) ﬂanking the SNPs of interest. PCR products were
gel-puriﬁed using the QIAquick Gel Extraction Kit (QIAgen) and Sanger
sequenced (GENEWIZ, Boston). The relative peak heights of the ALT and REF
alleles were measured. Extreme ASE events were conﬁrmed when the relative peak
height was 45.
Quality controls removed REF allele bias. Unless the ALT base causes NMD,
there should be no REF base versus ALT base expression bias in monoallelic SNPs.
Before removal of ‘low-quality’ genome-wide SNPs, 87.1% of ASE events express
the REF base, whereas after quality control,B50% of biased SNPs express the REF
base (Supplementary Fig. 2b).
Allele bias and ASE P value calculation. Allele bias and ASE P value were
calculated for each SNP that passed quality-control measures. If there were
multiple SNPs per gene, we either used phasing of SNPs (from maternal (mat) and
paternal (pat) alleles) or we made the assumption that if there are multiple SNPs in
a given gene, the expression bias will be unidirectional; that is, polymorphic bases
with higher expression are on the same allele. Allele bias was calculated as follows:
Reads containing heterozygous SNPs were counted and binned into one of
four categories, based on inheritance and expression: (1) maternal inheritance,
(2) paternal inheritance, (3) unknown inheritance with higher-allele expression and
(4) unknown inheritance with lower-allele expression. For each heterozygous SNP
in a gene, reads were summed into one of four allele categories (1) SNP-mat sum,
(2) SNP-pat sum, (3) SNP-higher-allele sum and (4) SNP-lower-allele sum. These
four allele categories were reduced to two, as follows:
If allele inheritance can be determined:
If SNP-mat sum4SNP-pat sum
Allele bias¼ (SNP-higher-allele sumþ SNP-mat sum)/(SNP-lower-allele
sumþ SNP-pat sum)
If SNP-pat sum4SNP-mat sum
Allele bias¼ (SNP-higher-allele sumþ SNP-pat sum)/(SNP-lower-allele
sumþ SNP-mat sum)
If allele inheritance is unknown:
Allele bias¼ SNP-higher-allele sum/SNP-lower-allele sum
ASE P value is calculated using a binomial distribution model, and
Bonferroni-corrected by the number of genes containing expressed heterozygous
SNPs for each sample (Supplementary Data 2 and 4).
The assumption that the more highly expressed bases at heterozygous SNP
positions are all on the same allele has the potential to introduce error into allele
bias and statistical assessment of ASE. We directly tested this approach by studying
F1 crosses of wild-type C57Bl6 and Castaneus mice. On the basis of parental mouse
strain germline DNA sequence (Mouse Genomes Project; Wellcome Trust Sanger
Institute), we estimated that F1 mice would have 18.5 million heterozygous SNPs,
encoded within 19,236 transcripts. To make this more comparable to human WGS
data, we only assessed every 18th heterozygous SNP. From RNAseq libraries
prepared from left and right atrium, left and right ventricle, pulmonary artery, liver
and skeletal muscle from P1 mice, we identiﬁed, on average, 14,678 expressed genes
including 9,312 expressed genes with heterozygous SNPs (Fig. 2a). We then
determined the false-positive rate of assigning unphased SNPs to alleles by
comparing fully phased SNPs to unphased SNPs while varying the minimum allele
bias (4 to 7-fold) and minimum read depth of monoallelic SNPs (4, 5,y 10) in
each condition (Supplementary Fig. 2c). We determined that an allele bias of 7.2,
with a minimum depth of ﬁve reads, yielded one false ASE event and 62 ‘true’ ASE
events (1.59% false-positive rate). The false-positive rate associated with assigning
SNPs to alleles was also assessed in three human WGS trios, using an allele bias of
7.2 and a minimum read depth of ﬁve. Fourteen ASE genes were called regardless
of whether phasing was used to assign alleles, or whether phasing was ignored.
Imprinted genes. Human genes previously identiﬁed as ‘imprinted’ in any tissue
were identiﬁed in either of two online databases (http://www.geneimprint.com and
www.otago.ac.nz/IGC). Genes with very low human fetal heart expression
(o2 r.p.m.) were excluded because they were unlikely to contribute to normal
heart development. Allele bias was calculated for each subject with heterozygous
SNPs, and ASE events identiﬁed as described above.
NMD analyses. NMD was assessed as described previously23. That is, the allele
carrying the LOF mutation was at least fourfold less than the normal allele and
read-depth sufﬁcient to suggest a statistically signiﬁcant (Po0.01) difference in
allele ratio. P values were Bonferroni-corrected for the number of heterozygous
nonsense mutations per subject (and not the number of expressed genes with
heterozygous SNPs), so many more ASE events associated with NMD were
identiﬁed than in our global ASE analyses.
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Expression analyses. We calculated both r.p.m. and reads per million aligned
reads per kilobase of transcript per gene per sample. On average, 15,479 genes
(range, 14,938–17,651) were expressed in cardiovascular tissues (Z2 r.p.m.; Fig. 1b
and Supplementary Table 1). Each sample was compared with the average
expression of all other samples of the same tissue type (fold change), and statistical
signiﬁcance was assessed by z-score. As quality control, tissue groups with more
than four samples were included in the analyses. Samples with 4100 highly
signiﬁcant expression differences (foldo0.2, Po0.05 or fold 45, Po0.05,
P calculated from z-score) were excluded from the analysis.
RNA expression of ASE genes, which demonstrated signiﬁcant downregulation
(foldo0.65, Po0.05) or signiﬁcant upregulation (fold 45, Po0.05), were based
on the expected fold change of B0.5 (allele loss of expression) and 47.2 (allele
gain of expression), and relaxed by 30% because of the variability in gender,
age and genotypes.
Fold downregulated: 0.5þ (0.5 0.3)¼ 0.65.
Fold upregulated: 7.2 (7.2 0.3)¼ 5.
For LOE analyses, we required a more stringent deﬁnition of signiﬁcant
downregulation (foldo0.1, Po2.7 10 3, P calculated from z-score).
This P value is based on a z-scoreo 3.
Reported LOE events (Table 3) are limited to polyadenylated transcripts
because RNAseq libraries were constructed from polyA-selected mRNA.
Quantitative RT–PCR. LOE events in CHD subjects, detected by RNAseq ana-
lyses, were conﬁrmed using qPCR. cDNA was prepared from 200 ng RNA from the
CHD proband and at least two matched tissue samples using Superscript III
Reverse Transcriptase (Thermo-Fisher). cDNA was PCR-ampliﬁed using Phusion
polymerase (New England Biolabs) with SYBR green and gene-speciﬁc primers
(Supplementary Table 12) and analysed using Fast Real-Time PCR (Applied
Biosystems). Housekeeping gene (ACTB, GAPDH, GUSB and PPIA) expression
was used to calculate DCt, and DDCt and P value (Student’s t-test) are reported in
Supplementary Table 10.
Data availability. Clinical and sequence data that support the ﬁndings of this
study have been deposited in dbGaP under accession phs000571. The data that
support the ﬁndings of this study are available from the corresponding author
upon request.
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